<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35075291</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>New antisense oligonucleotide therapies reach first base in ALS.</ArticleTitle><Pagination><StartPage>25</StartPage><EndPage>27</EndPage><MedlinePgn>25-27</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41591-021-01629-7</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Elia R</ForeName><Initials>ER</Initials><Identifier Source="ORCID">0000-0003-3867-1785</Identifier><AffiliationInfo><Affiliation>Therapeutic Development Branch, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borschel</LastName><ForeName>William F</ForeName><Initials>WF</Initials><AffiliationInfo><Affiliation>Therapeutic Development Branch, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Traynor</LastName><ForeName>Bryan J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Therapeutic Development Branch, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA. traynorb@mail.nih.gov.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA. traynorb@mail.nih.gov.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Z01 AG000949</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016376">Oligonucleotides, Antisense</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Nat Med. 2022 Jan;28(1):117-124</RefSource><PMID Version="1">34949835</PMID></CommentsCorrections><CommentsCorrections RefType="CommentOn"><RefSource>Nat Med. 2022 Jan;28(1):104-116</RefSource><PMID Version="1">35075293</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016376" MajorTopicYN="N">Oligonucleotides, Antisense</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>25</Day><Hour>5</Hour><Minute>49</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35075291</ArticleId><ArticleId IdType="doi">10.1038/s41591-021-01629-7</ArticleId><ArticleId IdType="pii">10.1038/s41591-021-01629-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Deng, H. X. et al. Science 261, 1047&#x2013;1051 (1993).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8351519</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen, D. R. et al. Nature 362, 59&#x2013;62 (1993).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel, R. S. et al. N. Engl. J. Med. 377, 1723&#x2013;1732 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1702752</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercuri, E. et al. N. Engl. J. Med. 378, 625&#x2013;635 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1710504</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran, H. et al. Nat. Med. https://doi.org/10.1038/s41591-021-01557-6 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01557-6</ArticleId><ArticleId IdType="pubmed">34949835</ArticleId></ArticleIdList></Reference><Reference><Citation>Korobeynikov, V. A. et al. Nat. Med. https://doi.org/10.1038/s41591-021-01615-z (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01615-z</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez, M. et al. Neuron 72, 245&#x2013;256 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton, A. E. et al. Neuron 72, 257&#x2013;268 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingwell, K. Nat. Rev. Drug Discov. 20, 412&#x2013;413 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41573-021-00088-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Biogen announces topline results from the tofersen phase 3 study and its open-label extension in SOD1-ALS. Biogen (17 October 2021).</Citation></Reference><Reference><Citation>Miller, T. et al. N. Engl. J. Med. 383, 109&#x2013;119 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId></ArticleIdList></Reference><Reference><Citation>Gennemark, P. et al. Sci. Transl. Med. 13, eabe9117 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abe9117</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata, T. et al. Nat. Biotechnol. https://doi.org/10.1038/s41587-021-00972-x (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-021-00972-x</ArticleId><ArticleId IdType="pubmed">34385691</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>